Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

This article has no abstract
Epistemonikos ID: 612b719549d22e5af115ccb0dd1c4484e25b08f4
First added on: Feb 07, 2025